American Society of Hematology

SHERPA: Blue

People

  1. Seshan
    Seshan
  2. Zelenetz
    Zelenetz
  3. Batlevi
    Batlevi
  4. Matasar
    Matasar
  5. Kumar
    Kumar
  6. Noy
    Noy
  7. Palomba
    Palomba
  8. Younes
    Younes
  9. Hamilton
    Hamilton
  10. Hamlin
    Hamlin

Groups

  1. Center for Hematologic Malignancies (25)
  2. Center for Pancreatic Cancer Research (25)
  3. Department of Medicine (25)
  4. Hematologic Malignancies, Division of (25)
  5. Survivorship Research (25)
  6. Epidemiology and Biostatistics (23)
  7. Executive Committee, Center for Hematologic Malignancies (21)
  8. Biostatistics Service (20)
  9. Sloan Kettering Institute Postdocs (18)
  10. GSK Faculty (17)
Search Within
  1. "Center for Hematologic Malignancies"
  2. "Center for Pancreatic Cancer Research"
  3. "Survivorship Research"
Formats
  1. Meeting Abstract (19)
  2. Journal Article (5)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (25)
  2. Center for Pancreatic Cancer Research (25)
  3. Department of Medicine (25)
  4. Hematologic Malignancies, Division of (25)
  5. Survivorship Research (25)
  6. Epidemiology and Biostatistics (23)

More Groups

People
  1. Venkatraman Seshan (15)
  2. Andrew Zelenetz (14)
  3. Connie Batlevi (13)
  4. Matthew Matasar (13)
  5. Ahmet Dogan (12)
  6. Anita Kumar (12)

More People

Years
  1. 2023 (3)
  2. 2022 (2)
  3. 2021 (5)
  4. 2020 (4)
  5. 2019 (2)
  6. 2018 (2)

More Years

Publications
  1. Blood (22)
  2. Blood Advances (3)

Results (25)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetic alterations of follicular lymphoma can predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Fregonese, B.; Seshan, V.; Hajj, C.; Cederquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clonal hematopoiesis in survivors of childhood cancer
    Research Letter

    Friedman, D. N.; Chan, I. C. C.; Moskowitz, C. S.; Li, S.; Turner, K.; Liu, J.; Bouvier, N.; Walsh, M. F.; Spitzer, B.; Kung, A. L.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
    Journal Article

    Qualls, D.; Lam, H. Y.; Whiting, K.; Kumar, A.; Matasar, M.; Owens, C.; Nichols, C.; Espeleta, J. A.; Qiu, A.; Subzwari, S.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors
    Journal Article

    Dunbar, A.; Bolton, K. L.; Devlin, S. M.; Sanchez-Vega, F.; Gao, J.; Mones, J. V.; Wills, J.; Kelly, D.; Farina, M.; Cordner, K. B.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
    Journal Article

    Bobillo, S.; Joffe, E.; Lavery, J. A.; Sermer, D.; Ghione, P.; Noy, A.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save